Authors
Latest:
Dr. Warner on the Future of Surgery for Patients With Prostate CancerJonathan N. Warner, MD, reconstructive urologist, City of Hope, discusses the future of surgery for patients with prostate cancer.
Latest:
Dr Strosberg on 212Pb-DOTAMTATE in Unresectable/Metastatic SSTR+ GEP-NETsJonathan Strosberg, MD, discusses safety data for 212Pb-DOTAMTATE in metastatic somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors.
Latest:
Dr Riess on Treatment Developments in ALK+ and ROS1+ NSCLCJonathan Wesley Riess, MD, MS, discusses developments in the treatment of patients with NSCLC harboring ALK or ROS1 rearrangements.
Latest:
Navigating Treatment Choices: Clinically Meaningful Outcomes to Look for in HERTHENA-Lung02This episode discusses the desired outcomes from the HERTHENA-Lung02 trial that would justify using HER3-DXd before platinum and pemetrexed chemotherapy while also exploring the potential benefits of amivantamab, including its PFS advantage and the observed trend toward improved OS in this treatment setting.
Latest:
Flaxseed Ineffective in Controlling Hot FlashesFlaxseed had no effect on reducing hot flashes in postmenopausal women who reported experiencing 28 or more hot flashes per week.
Latest:
Dr. Berek Discusses the Impact of PARP Inhibitors on Ovarian CancerJonathan S. Berek, MD, MMS, Laurie Kraus Lacob Professor, Stanford University School of Medicine, director, Stanford Women’s Cancer Center, senior advisor, Stanford Cancer Institute, discusses the impact of PARP inhibitors on the treatment landscape of ovarian cancer.
Latest:
Dr. Strosberg Discusses Updates From the NETTER-1 StudyJonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses updates from the NETTER-1 study in patients with neuroendocrine tumors (NETs).
Latest:
Cloud Computing for FellowsCloud computing refers to Web-based programs that allow the user to store information in a central location, typically not the device being used to access the information (such as your laptop, desktop PC, or iPad).
Latest:
Future Directions in Biomarker-Based OncologyExperts in oncology discuss future directions in biomarker-driven therapy.
Latest:
Dr. Tward on Abbreviated Course ADT for Prostate CancerJonathan Tward, MD, PhD, Associate Professor of Radiation Oncology at the Huntsman Cancer Institute, discusses abbreviated course androgen-deprivation therapy (ADT) for prostate cancer treatment.
Latest:
Rituximab Sets the Pace in Changing Lymphoma LandscapeRituximab is used ubiquitously in the treatment of B-cell lymphomas, and has set the paradigm the field has been trying to match in drug development.
Latest:
Dr. Goldman on Key Takeaways From the CASPIAN Trial in Frontline ES-SCLCJonathan W. Goldman, MD, discusses key takeaways from the phase 3 CASPIAN trial in patients with extensive-stage small cell lung cancer.
Latest:
Experts on the Management of Diarrhea Associated With EGFR TKIsZosia Piotrowska, MD, Jonathan Riess, MD, MS, Gregory Riely, MD, Emily Skotte, MSN, APRN, ACNP-BC, and Amanda Cass, PharmD, BCPS, discuss the management of diarrhea as an adverse effect associated with EGFR TKIs.
Latest:
Dr Cohen on Available Treatments For MCLJonathon B. Cohen, MD, MS, discusses the background of the BRUIN study of pirtobrutinib in previously treated patients with mantle cell lymphoma.
Latest:
Dr Cohen on Treatment Considerations for Relapsed/Refractory MCLJonathon B. Cohen, MD, MS, discusses treatment considerations for mantle cell lymphoma and the role of pirtobrutinib in the management of this disease.
Latest:
Retesting for FLT3 Mutation Status in AMLJordan Clark, the chief commercial officer at Diaceutics, discusses FLT3 retesting in a relapsed acute myeloid leukemia setting.
Latest:
Dr. Berlin on Unmet Needs in Pancreatic CancerJordan D. Berlin, MD, discusses unmet needs in pancreatic cancer.
Latest:
Dr. Gauthier on Potential for CAR T Cells in CLLJordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor T-cell therapy in the treatment of chronic lymphocytic leukemia.
Latest:
Despite Benefits, Screening for Lynch Syndrome Often OverlookedMuch work needs to be done to increase Lynch syndrome screening rates and better understand the factors that are associated with low testing rates.
Latest:
Dr. Bruix Discusses Progress of Second-Line Treatment in HCCJordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the impact of the recent progress in the second-line treatment setting for hepatocellular carcinoma.
Latest:
Dr. Giralt on Mucoadhesive Clonidine in Head and Neck CancerJordi Giralt, MD, PhD, pathology, radiology, oncology, University Hospital Vall d'Hebron, discusses a study that examined mucoadhesive clonidine (Clonidine Lauriad) in the prevention of severe radiomucositis in patients with head and neck cancer.
Latest:
Dr. Jorge Garcia on METEOR Trial for RCCJorge A. Garcia, MD, Department of Hematology and Oncology, discusses the results of the phase III METEOR trial, which compared the efficacy of cabozantinib (Cabometyx) versus everolimus (Afinitor) in patients with advanced renal cell carcinoma.
Latest:
Dr Cortes on the Phase 4 BYOND Study in Previously Treated Patients With CMLJorge E. Cortes, MD, discusses efficacy and safety findings from the phase 4 BYOND study in previously treated patients with Ph+ chronic myeloid leukemia.
